Post Marketing Surveillance Study of the Labeled Use of Remicade (Infliximab) in Patients With Chronic Inflammatory Diseases.

Trial Profile

Post Marketing Surveillance Study of the Labeled Use of Remicade (Infliximab) in Patients With Chronic Inflammatory Diseases.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms REMission
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 11 Sep 2012 Drug company changed from Schering Plough to Merck & Co as reported by ClinicalTrials.gov.
    • 17 Oct 2011 Actual patient no is 3000 as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top